11 Oct 2022

SARS-CoV-2 Variant Detection

World Health Organization (WHO) has been monitoring and assessing the evolution of SARS-CoV-2 since January 2020, and the emergence of new strains in recent months has triggered the characterisation of SARS-CoV-2 variants.

Veredus Laboratories is continuously monitoring the global situation of COVID-19 pandemic and conducting extensive impact assessment of SARS-CoV-2 variants on **VereCoV™ OneMix Detection Assay, VereRT™ COVID-19 PCR Assay**, **VereRT™ ZeroPrep™ COVID-19 PCR Assay, VereRT™ Duo COVID-19 PCR Assay and VereRT™ ZeroPrep™ Duo COVID-19 PCR Assay**

As of 11 October 2022, Veredus' latest bioinformatic check against the XBB lineage with GISAID database has confirmed that, amongst respective deposited sequences in the database, the abovementioned Veredus' detection assays are able to confidently detect for the XBB lineage, independently.

A summary of our analysis is tabulated below.

WHO VOC Classification	Lineage	(No. of detection incompatibility) / (Total no. of SARS-CoV-2 genome cross-checked against)	Detectability using VereRT™ COVID-19 PCR Kit	Detectability using VereRT™ ZeroPrep™ COVID-19 PCR Kit	Detectability using VereRT™Duo COVID-19 PCR Kit	Detectability using VereRT™ ZeroPrep™ Duo COVID-19 PCR Kit	Detectability using VereCoV™ OneMix Detection Kit
N.A.	XBB^	0 / 206	100%*	100%*	100%**	100%**	100%***

^ Includes sub-lineages
* At least 1 of the 2 N gene targets is detectable
** At least N gene or ORF gene target is detecable
*** At least 2 of the 5 target regions on the VereChip™ are detectable

83 Science Park Drive #04-02
Singapore 118258
T: (65) 6496 8600 **F**: (65) 6779 2680

vereduslabs.com

Company Registration Number: 200305085G